Nasal Polyposis - Pipeline Insight, 2024

This “Nasal Polyps - Pipeline Insight, 2024,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Nasal Polyps pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Nasal Polyps Understanding

Nasal Polyps: Overview

A nasal polyp (also called Nasal Polyps) is a benign (noncancerous) tumor that grows from the lining of the nose or sinuses. These polyps usually occur in both the right and left nasal passages and obstruct the flow of air. They can make your nose feel stuffy, and can decrease your sense of smell. Not all growths in the nose are polyps. Nasal polyps may result from chronic (long-lasting) inflammation of the lining of the nose, although they often occur for no apparent reason. People with chronic hay fever (allergic rhinitis) are more likely than others to develop nasal polyps. In addition, nasal polyps commonly develop in children with cystic fibrosis.

Nasal Polyps - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nasal Polyps pipeline landscape is provided which includes the disease overview and Nasal Polyps treatment guidelines. The assessment part of the report embraces, in depth Nasal Polyps commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nasal Polyps collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Nasal Polyps R&D. The therapies under development are focused on novel approaches to treat/improve Nasal Polyps.

Nasal Polyps Emerging Drugs Chapters

This segment of the Nasal Polyps report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nasal Polyps Emerging Drugs

Benralizumab: Astra ZenecaBenralizumab is a monoclonal antibody that attracts natural killer cells via antibody-dependent cellular cytotoxicity activity (ADCC activity) to induce direct and rapid depletion of eosinophils in the blood and in the airway. The drug is in phase 3 of clinical trials for the treatment of severe NasalPolyps.

AK001: Allakos AK001 is a therapeutic antibody that targets a receptor present on eosinophils and mast cells. Binding of antibody to this receptor causes inhibition of mast cell activity and selective depletion of activated eosinophils. AK001's action is highly specific to mast cells and eosinophils and has potential to be of benefit in a wide spectrum of conditions where these cells are involved. It is currently in phase 2 of clinical trial for the treatment of NasalPolyps.

Nasal Polyps: Therapeutic Assessment

This segment of the report provides insights about the different Nasal Polyps drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Nasal Polyps

There are approx. 4+ key companies which are developing the therapies for Nasal Polyps. The companies which have their Nasal Polyps drug candidates in the most advanced stage, i.e. phase III include AstraZeneca.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Nasal Polyps pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nasal Polyps: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nasal Polyps therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nasal Polyps drugs.

Nasal Polyps Report Insights

• Nasal Polyps Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Nasal Polyps Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Nasal Polyps drugs?
• How many Nasal Polyps drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nasal Polyps?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nasal Polyps therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Nasal Polyps and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AstraZeneca.
• Allakos
• Idorsia Pharmaceuticals
• Novartis

Key Products

• Benralizumab
• AK001
• ACT-774312
• Fevipiprant